A detailed history of Cibc Private Wealth Group, LLC transactions in Genmab A/S stock. As of the latest transaction made, Cibc Private Wealth Group, LLC holds 3,345 shares of GMAB stock, worth $68,873. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,345
Previous 3,332 0.39%
Holding current value
$68,873
Previous $83,000 2.41%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$23.84 - $28.48 $309 - $370
13 Added 0.39%
3,345 $81,000
Q2 2024

Aug 09, 2024

BUY
$25.13 - $30.27 $276 - $332
11 Added 0.33%
3,332 $83,000
Q1 2024

May 10, 2024

BUY
$26.43 - $32.77 $87,774 - $108,829
3,321 New
3,321 $99,000
Q3 2023

Nov 13, 2023

BUY
$35.27 - $42.24 $212,360 - $254,327
6,021 New
6,021 $212,000
Q1 2022

May 16, 2022

BUY
$30.95 - $39.68 $96,564 - $123,801
3,120 New
3,120 $113,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Cibc Private Wealth Group, LLC Portfolio

Follow Cibc Private Wealth Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Private Wealth Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Private Wealth Group, LLC with notifications on news.